Medicaid Monitor
Policy Intelligence
Medicaid Monitor
Policy Intelligence
© 2026 Lanphier Ventures, LLC
Informational use only. Not legal or compliance advice.
← All stories
Industry·June 23, 2026

Inventia Healthcare recalls 11,460 bottles of chlorthalidone tablets after dissolution failure

Inventia Healthcare Limited is recalling 11,460 bottles of Chlorthalidone Tablets USP, 25 mg, distributed nationwide after the product failed dissolution specifications. The FDA classified the recall as Class II on June 22, following the manufacturer's June 5 recall initiation. Chlorthalidone is a diuretic used to treat hypertension. Class II recalls indicate the product may cause temporary or medically reversible adverse health consequences, with a remote probability of serious harm.

Why it matters for managed care

Medicaid managed care organizations should verify pharmacy networks are distributing replacement chlorthalidone products and confirm members on affected lots receive substitute medications to maintain hypertension management continuity.

Pharmacy · Managed Care

Read the full article at beckershospitalreview.com

Share this briefing

You might also like

← All stories

Get the daily briefing.